Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

Abstract Background The combination of immunotherapy and chemotherapy has demonstrated an enhancement in progression-free survival (PFS) for individuals with advanced and metastatic triple-negative breast cancer (TNBC) when compared to the use of chemotherapy alone. Nevertheless, the extent to which...

Full description

Saved in:
Bibliographic Details
Main Authors: Shengfa Lin, Bihe Fu, Muhammad Khan
Format: Article
Language:English
Published: BMC 2024-12-01
Series:World Journal of Surgical Oncology
Subjects:
Breast cancer
Immunotherapy
Immune checkpoint inhibitors (ICI)
Pembrolizumab
Atezolizumab
Progression-free survival
Online Access:https://doi.org/10.1186/s12957-024-03424-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12957-024-03424-3

Similar Items